Teva Pharmaceuticals Announces Positive Phase 2a Results for Investigational Celiac Disease Treatment
On September 2nd, 2026, Teva Pharmaceutical Industries announced positive topline results from a Phase 2a clinical trial of TEV ’408, an investigational drug designed to block interleukin-15 (IL-15). IL-15 acts…
Continue Reading